← Human Trials & Peer-Reviewed Studies
Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans
Plain-language guide to PMID 28345790 (2017): single-blind randomized controlled trial study of Pancreatic Polypeptide and Ghrelin.
Key Facts
- PMID
- 28345790
- Journal
- Diabetes, obesity & metabolism
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Tamboli RA et al. (11 authors)
- DOI
- 10.1111/dom.12952
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Pancreatic Polypeptide and Ghrelin.
Ghrelin is a gastric-derived hormone that stimulates growth hormone (GH) secretion and has a multi-faceted role in the regulation of energy homeostasis, including glucose metabolism.
Circulating ghrelin concentrations are modulated in response to nutritional status, but responses to ghrelin in altered metabolic states are poorly understood.
The researchers investigated the metabolic effects of ghrelin in obesity and early after Roux-en-Y gastric bypass (RYGB).
How the Study Was Run
The researchers set it up as a randomized, single-blind and crossover study.
The participants were allocated by chance, so the Pancreatic Polypeptide group and the comparison group should start out alike.
Only one side, usually the participants, was kept unaware of whether Pancreatic Polypeptide was given.
In the crossover set-up each of the participants took both Pancreatic Polypeptide and the comparison in turn, acting as their own control.
Central responses were assessed by GH and pancreatic polypeptide (surrogate for vagal activity) secretion.
Peripheral responses were assessed by hepatic and skeletal muscle insulin sensitivity during a hyperinsulinaemic-euglycaemic clamp.
What Was Measured
PubMed files the paper under topics including Acylation, Anti-Obesity Agents, Cohort Studies, Combined Modality Therapy, Energy Metabolism, Gastric Bypass and Ghrelin.
Author keywords: bariatric surgery, glucose metabolism and insulin resistance.
What This Means in Plain Language
The paper is a randomized, single-blind and crossover study of Pancreatic Polypeptide and Ghrelin.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Pancreatic Polypeptide compound page and the Ghrelin compound page, all human trials.
Our Notes on the Compounds
Pancreatic Polypeptide: A 36-amino-acid pancreatic hormone in the same family as peptide YY and neuropeptide Y.
Ghrelin: A 28-amino-acid stomach hormone that signals hunger and triggers growth hormone release; studied in human trials as an infusion.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.